Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2026-02-01

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

• Phase: PHASE3

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: retatrutide